Kura Oncology, Inc.
11119 North Torrey Pines Road
Suite 125
La Jolla, CA 92037
(858) 500-8800
April 12, 2016
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Irene J. Paik
Re: | Kura Oncology, Inc. |
Registration Statement on Form S-3
Filed: April 5, 2016
File No. 333-210614
Ladies and Gentlemen:
Kura Oncology, Inc. (the Registrant) hereby requests that the Securities and Exchange Commission (the Commission) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:00 p.m. Eastern Time on Thursday, April 14, 2016, or as soon thereafter as is practicable. The Registrant also hereby requests a copy of the written order verifying the effective date.
In connection with this request, the Registrant hereby acknowledges that:
| should the Commission or the staff of the Commission (the Staff), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; |
| the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and |
| the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |
Sincerely,
KURA ONCOLOGY, INC. | ||
By: | /s/ Heidi Henson | |
Heidi Henson | ||
Chief Financial Officer |
cc: | Charles J. Bair, Cooley LLP |
James Pennington, Cooley LLP